Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas (Q36596874)

15 August 2017

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas (English)

1 reference

15 August 2017

Olivier Elemento

0 references

Gabriela Chiosis

Gabriela Chiosis

0 references

Leandro Cerchietti

Leandro Cerchietti

0 references

Giorgio Inghirami

Giorgio Inghirami

0 references

Rodolfo Machiorlatti

Rodolfo Machiorlatti

1 reference

15 August 2017

Fabrizio Tabbò

1 reference

15 August 2017

Rossella Marullo

0 references

Paola Ghione

0 references

Marco Ladetto

0 references

Marcello Gaudiano

1 reference

15 August 2017

Biljana Culjkovic-Kraljacic

1 reference

15 August 2017

Tharu M Fernando

1 reference

15 August 2017

Nieves Calvo-Vidal

1 reference

15 August 2017

Akanksha Verma

1 reference

15 August 2017

ShaoNing Yang

1 reference

15 August 2017

Hiba Zahreddine

1 reference

15 August 2017

Rebecca L Goldstein

1 reference

15 August 2017

Jayeshkumar Patel

1 reference

15 August 2017

Tony Taldone

1 reference

15 August 2017

Giorgio Inghirami

1 reference

15 August 2017

Ari Melnick

1 reference

15 August 2017

Katherine L B Borden

1 reference

15 August 2017

language of work or name

English

0 references

publication date

24 November 2015

1 reference

15 August 2017

1 reference

15 August 2017

127

1 reference

15 August 2017

1 reference

15 August 2017

858-868

1 reference

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Differential Requirements for eIF4E Dose in Normal Development and Cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

The role of heat shock proteins in cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Selective targeting of the stress chaperome as a therapeutic strategy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Targeting the dynamic HSP90 complex in cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

eIF4E is a central node of an RNA regulon that governs cellular proliferation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

eIF4E--from translation to transformation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4760090

10.1182/BLOOD-2015-05-645069

20 September 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

26603836

1 reference